The Lead Episode 132: A Discussion of Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation (Japanese Language Episode)-The Lead Episode 132 Bonus Video File (Japanese Episode)

The Lead Episode 132 Bonus Video File (Japanese Episode)

Video Transcription

Video Summary

In the Lead Podcast episode discussing the Ocean Trial, experts reviewed a study on antithrombotic therapy after successful cardiac ablation. The randomized trial compared rivaroxaban to aspirin in patients without atrial fibrillation recurrence, with an average age of 66 and moderate stroke risk scores. Results showed no significant difference in thrombotic events between groups, but rivaroxaban had a higher bleeding risk. The data suggest that continuing anticoagulation may be unnecessary for many post-ablation patients with low to moderate risk, aligning with updated clinical guidelines. Future strategies might involve personalized treatment based on additional biomarkers like atrial amyloidosis.

Keywords

Ocean Trial

antithrombotic therapy

cardiac ablation

rivaroxaban vs aspirin

atrial amyloidosis